Monday, January 30, 2012

anti-CD98hc by Lian at University of Tokushima

Paper Title: Manipulation of CD98 resolves type 1 diabetes in nonobese diabetic mice.

Quote from the Abstract:
Injection of the anti-CD98hc [monoclonal antibody] completely prevented the onset of cyclophosphamide-induced diabetes in NOD mice. Treatment of diabetic NOD mice with anti-CD98hc reversed the diabetic state to normal levels, .... Furthermore, treatment of diabetic NOD mice with CD98hc small interfering RNA resolved T1D. These data indicate that strategies targeting CD98hc might have clinical application for treating T1D


Saturday, January 28, 2012

Protein and Nanoparticle by Santamaria at Parvus

Parvus, which is basically Santamaria, Coggins and Jord Cowan and two of them still have day jobs has spent the last 18 months testing the treatment on mice.
With 70 per cent to 80 per cent of the animals permanently free of diabetes after receiving the injections, according to Coggins, the company is now looking to raise $30 million to move to clinical trials.
Even the 20 to 30 per cent of mice who relapse see the disease disappear after another round of treatment, Coggins said.

News article:

Sunday, January 1, 2012

Catenarin by Shen at Taiwan

Quote from Abstract:
Overall, the data demonstrate the preventive effect and molecular mechanism of action of catenarin on T1D, suggesting its novel use as a prophylactic agent in T1D.

Full paper: